Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway

被引：3

作者：

Kawaguchi, Tomoyuki ^{[1
]}

Okamoto, Koichi ^{[1
]}

Fujimoto, Shota ^{[1
]}

Bando, Masahiro ^{[1
]}

Wada, Hironori ^{[1
]}

Miyamoto, Hiroshi ^{[1
]}

Sato, Yasushi ^{[2
]}

Muguruma, Naoki ^{[1
]}

Horimoto, Katsuhisa ^{[3
,4
]}

Takayama, Tetsuji ^{[1
]}

机构：

[1] Tokushima Univ, Inst Biomed Sci, Dept Gastroenterol & Oncol, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan

[2] Tokushima Univ, Dept Community Med Gastroenterol & Oncol, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan

[3] AIST, Mol Profiling Res Ctr Drug Discovery Molprof, 2-3-26 Aomi,Koto Ku, Tokyo 1350064, Japan

[4] SOCIUM Inc, 2-4-7 Aomi,Koto ku, Tokyo 1350064, Japan

来源：

JOURNAL OF GASTROENTEROLOGY | 2024年 / 59卷 / 01期

关键词：

Sessile serrated lesion; Chemoprevention; Connectivity map; Organoid; Lansoprazole; PROTON PUMP INHIBITORS; HUMAN COLON; DNA METHYLATION; BRAF MUTATION; CANCER CELLS; POLYPS; PROSTATE; GROWTH; TUMORS;

D O I：

10.1007/s00535-023-02052-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundAlthough the serrated-neoplasia pathway reportedly accounts for 15-30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL.MethodsWe generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis.ResultsWe identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 mu M) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs.ConclusionsOur data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells.

引用

页码：11 / 23

页数：13